Golgi and Breye partner to develop P2X7 receptor antagonist programme
25 Jul 2023
Preview
Source: Pharmaceutical Technology
Diabetic retinopathy is one of the main reasons for blindness among working-age adults. Credit: Alexander Grey from Pixabay.
Golgi Neurosciences has joined forces with Breye Therapeutics for the development of a P2X7 receptor antagonistP2X7 receptor antagonist programme.
The receptor, a vital inflammation switch, is an adenosine triphosphate (ATP) gated ion channel found in several cell types.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsBeta 2 Adrenergic Receptor (Beta 2 Adrenoreceptor or ADRB2) Drugs in Development by Therapy Areas... GlobalData
Preview
Source: Pharmaceutical Technology
ReportsD2 Dopamine Receptor (Dopamine D2 Receptor or DRD2) Drugs in Development by Therapy Areas and Ind... GlobalData
View allCompanies IntelligenceBreye Therapeutics ApSView all
The oral P2X7 receptor antagonistsP2X7 receptor antagonists offer a new treatment approach for both early-stage diabetic retinopathy (DR) and dry age-related macular degeneration (dry AMD)AMD).
Golgi Neurosciences managing director Chiara Liberati said: “With leading experts on the Scientific Advisory Board, Breye is led by a strong and seasoned Management team, supported by a highly-regarded syndicate of investors, making Breye the ideal partner to facilitate the next steps in advancing our P2X7 receptor antagonist program towards developing innovative approaches for retinal disorders.”
AMD is a significant factor contributing to the loss of vision, especially among individuals aged 60 years and older.
Breye Therapeutics CEO Ulrik Mouritzen said: “The Golgi incubator has fantastic expertise in neurosciences, and we are pleased to collaborate to advance the P2X7 receptor antagonistP2X7 receptor antagonist programme for retinal disorders, where there is a large unmet medical need for more effective and less burdensome therapies.”
Based in Milan, Italy, Golgi is involved in the discovery and development of small molecule-based therapies for neurodegenerative diseases.
Breye is focused on the development of novel, oral ophthalmology drugs for DR and AMD.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.